At Legend Biotech, we are transforming the world of oncology and medicine, and always looking for people who can help contribute to the strength of our team and to our shared values.
We are actively hiring across multiple functions and levels to strengthen our world-class team with our goal and commitment to improving patients' lives through transformative science and medicine.
To view and apply for one of our current open positions,
Legend Biotech has entered into a worldwide collaboration and
license agreement with Janssen Biotech, Inc., one of the Janssen
Pharmaceutical Companies of Johnson & Johnson, to develop,
manufacture, and commercialize LCAR-B38M (JNJ-68284528/JNJ-4528).
Under the terms of the agreement, Legend and Janssen are co-developing and will
Legend received clearance from China National Medical Products Administration in March 2018 for a Phase 2 registration study in China, and Janssen Biotech, Inc. received US Food and Drug Administration clearance for an Investigational New Drug Application in May 2018 and has since initiated a Phase 1b/2 study intended for registration in the United States and EU.
JNJ-4528 was granted Orphan designation by the US FDA in February 2019 followed by PRIME designation in the EU by the EMA in April 2019.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
*LCAR-B38M identifies the investigational product being studied in China and Janssen Biotech, Inc.'s JNJ-68284528 (also referenced as JNJ-4528) identifies the investigational product being studied in the United States, both of which are representative of the same CAR-T cell therapy.
You are about to leave LegendBiotech.com.
Are you sure you want to leave so soon?